Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Rudd

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Journal of Medicinal Chemistry|March 25, 2016
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's DiseaseShawn J Stachel, Celina Zerbinatti, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Science Translational Medicine|January 12, 2022
The PET tracer [<sup>11</sup>C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's diseaseWenping Li, Yuchuan Wang, Talakad G Lohith, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease InhibitorsUnmesh Shah, Charles Jayne, Samuel Chackalamannil, et al.
Bioorganic & Medicinal Chemistry Letters|October 23, 2012
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkersMichael T Rudd, Charles J McIntyre, Joseph J Romano, et al.
Journal of Medicinal Chemistry|March 25, 2016
Identification and in Vivo Evaluation of Liver X Receptor β-Selective Agonists for the Potential Treatment of Alzheimer's DiseaseShawn J Stachel, Celina Zerbinatti, Michael T Rudd, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2012
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A proteaseMichael T Rudd, John A McCauley, Joseph J Romano, et al.
Chemmedchem|March 12, 2015
P2-quinazolinones and bis-macrocycles as new templates for next-generation hepatitis C virus NS3/4a protease inhibitors: discovery of MK-2748 and MK-6325Michael T Rudd, John W Butcher, Kevin T Nguyen, et al.
ACS Medicinal Chemistry Letters|August 16, 2023
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric ModulatorMichael T Rudd, Peter J Manley, Barbara Hanney, et al.
Science Translational Medicine|January 12, 2022
The PET tracer [<sup>11</sup>C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's diseaseWenping Li, Yuchuan Wang, Talakad G Lohith, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease InhibitorSteven Harper, John A McCauley, Michael T Rudd, et al.
Pageof 14